PeerVoice Endocrinology & Metabolic Disorders Video PeerVoice

Visit https://www.peervoice.com/DKG860 to view the entire programme with slides. After completing “Ronald M. Goldenberg, MD, FRCPC, FACE - When Less Is More: How Emerging Once-Weekly Insulins May Enhance Patient-Centred Care for Persons With Type 2 Diabetes”, participants will be able to: Outline the role of basal insulin in people with type 2 diabetes (T2D) who require treatment intensification to achieve glycemic targets; Review the barriers to treatment intensification with injectable therapies and how they may be addressed in people with T2D; Evaluate the latest evidence comparing once-weekly basal insulins with once-daily insulins and the clinical implications of the data; and Discuss practical strategies that integrate once-weekly basal insulins into clinical practice, once available.

Visit https://www.peervoice.com/GBR860 to view the entire programme with slides. After completing “Maria Craig, MBBS, PhD, FRACP, MMed(ClinEpid) - Treating T2D in People of Younger Age in This Day and Age: How Would You Manage These Children and Adolescents With T2D?”, participants will be able to: Evaluate the efficacy and safety evidence for recommended interventions to manage type 2 diabetes (T2D) in children and adolescents; Describe age-, disease-, and treatment-related considerations which impact decision-making in the treatment of T2D in children and adolescents; and Propose evidence-based, guideline-recommended management plans for children and adolescents with T2D.

Visit https://www.peervoice.com/JPS860 to view the entire programme with slides. After completing “Alex Abitbol, MDCM, FRCPC - Next Generation Basal Insulins: From Once Daily to Once Weekly Injections”, participants will be able to: Discuss the latest clinical evidence with existing and emerging long-acting basal insulin analogues in the treatment of patients with type 2 diabetes (T2D); Identify steps for successful basal insulin analogue therapy, including proper initiation and patient education; and Outline effective strategies for glucose monitoring in patients on basal insulin, including how to use continuous glucose monitoring to optimize T2D management.

Visit https://www.peervoice.com/ETM860 to view the entire programme with slides. After completing “Alice YY Cheng, MD, FRCPC - Addressing Unmet Needs in Patients With T2D and CKD: Stepping Up Care to Improve Cardiorenal Outcomes”, participants will be able to: Outline morbidity and mortality risks for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) and current unmet needs in this patient population; Discuss best practices to identify and assess risk in patients with T2D and early CKD in primary care; Evaluate the role of non-steroidal mineralocorticoid receptor antagonist (nsMRA) therapy in the context of current treatment options for patients with T2D and CKD; and Apply best practices to monitor response and mitigate or manage safety concerns in patients receiving nsMRA therapy.

Visit https://www.peervoice.com/QKR860 to view the entire programme with slides. After completing “Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes”, participants will be able to: Use recommended screening tests to identify chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety evidence guiding the use of novel treatments for CKD in T2DM; and Apply best practices for the initiation and management of novel therapies for treatment of CKD and T2DM.

Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) on the current 2024 COVID-19 vaccination roll-out.